General OA media and info, page-553

Denial, love your work, you’ve been superb. You and I both understand the unique proposition if 2mg gets up. I hope a global pharma does too!

But, it wasn’t a rhetorical question, I said that post stage 2, AA was still an option and DMOAD (on the label) could still be considered too (down the track).

A partner tipping in for stage 2 costs and all these levers to pull on, alive and well…. Well it seems our MC might multiply pending the imminent regulatory outcomes from our OUTSTANDING datasets.

003 yes, but if we apply for AA, and it’s accepted, 003 might covert to a phase 4 study and that might contain the DMOAD monitoring and data generation while our compound is commercially available and bringing in revenue.